IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$2.09
+1.46%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.07
- Revenue estimate
- $6.1K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.07
- Revenue actual
- —
- Revenue estimate
- $6.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -3.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $7.00
- PT range
- $6.00 – $8.00
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.07 | -$0.11 | Miss -65.12% | — |
| May 7, 2026 | -$0.17 | -$0.09 | Beat 47.06% | — |
| Mar 19, 2026 | -$0.18 | -$0.17 | Beat 5.56% | -$17.6K |
| Aug 7, 2025 | -$0.24 | -$0.24 | In line | $46.4K |
| Mar 20, 2025 | -$0.27 | -$0.09 | Beat 66.67% | -$438 |
| Nov 8, 2024 | -$0.27 | -$0.33 | Miss -22.22% | $135.8K |
| Aug 8, 2024 | -$0.21 | -$0.26 | Miss -23.81% | $6.8K |
| Mar 21, 2024 | -$0.20 | -$0.30 | Miss -50.00% | — |
| Nov 1, 2023 | -$0.29 | -$0.14 | Beat 51.72% | $64.1K |
| Aug 10, 2023 | -$0.36 | -$0.15 | Beat 58.33% | — |
| May 11, 2023 | -$0.30 | -$0.27 | Beat 10.00% | — |
| Mar 22, 2023 | $0.25 | -$0.18 | Miss -172.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026